Why the study?
What are the cardiovascular toxicities associated with tyrosine kinase inhibitors and how should they be managed?
What are the cardiovascular toxicities associated with tyrosine kinase inhibitors and how should they be managed?
This review highlights the importance of early detection and management of cardiovascular toxicities associated with tyrosine kinase inhibitors in cancer patients.
May warrant CV monitoring in TKI-treated patients; extends prior reviews by stressing reversibility for risk-benefit decisions.
INTRODUCTION: Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the management of many malignancies. However, they also have been shown to be associated with a certain degree of cardiovascular side effects that are often reversible. AREAS COVERED: As the number of new TKIs continues to grow, it is expected that clinicians will be facing the challenge of early detection and 10 management of these side effects while balancing the risk-benefit ratios of continuing with life-saving cancer therapy medications. This review will present the current knowledge related to incidence and proposed mechanisms of cardiovascular side effects of TKIs and also discuss treatment recommendations when available EXPERT OPINION: We will present and discuss available data and suggest recommendations related to patient monitoring and early identification of TKIs related cardiovascular toxities.
No takes yet. Share an insight, caveat, or question.
Mouhayar et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: